Harvard University

Dixie-Lee Esseltine joins HBS Kraft Precision Medicine Accelerator

Friday, September 29, 2017

Dr. Dixie-Lee Esseltine, formerly the Vice President of Global Clinical Development at Takeda Pharmaceuticals, recently joined the Harvard Business School’s (HBS) Kraft Precision Medicine Accelerator. Esseltine will lead the Accelerator’s Clinical Trials work stream, which is comprised of leading nonprofit organizations (NPOs) and clinical leaders focused on precision medicine. The goal of this work stream is to accelerate the advancement of innovative platform trials across cancers by identifying best practices and sharing knowledge, helping NPOs build their understanding of the design and operation of master protocols, and working with the FDA to improve master protocols.

[Read More]

James Ostell named National Center for Biotechnology Information director

Thursday, September 14, 2017

National Library of Medicine (NLM) Director Patricia Flatley Brennan, R.N., Ph.D., has appointed James M. Ostell, Ph.D., as the director of the National Center for Biotechnology Information (NCBI), a division of NLM at the NIH. Dr. Ostell has been with NCBI since it was established by Congress in 1988, and has helped shape it into one of the most widely used biomedical resources in the world. 

[Read More]

Improved perception of the industry

Monday, June 12, 2017

The 2017 Global Pharmaceutical Reptrak study, prepared each year by Boston’s Reputation Institute, showed that the public’s perception of the pharmaceutical industry has improved, earning an industry score of 71.8, up from 68.2 in 2016. Furthermore, about 44% of respondents viewed the industry as having an excellent reputation, a seven point increase since 2016. Similarly, the number of respondents who perceived the industry as weak or poor declined, moving to 26% from 35% in 2016.

[Read More]

Cellular Dynamics International, Harvard Stem Cell Institute to collaborate

Thursday, April 20, 2017

Cellular Dynamics International (CDI), a FUJIFILM company and a developer and manufacturer of induced pluripotent stem cells (iPS), has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the University to its affiliated hospitals and the biomedical industry. The objective of the new partnership is to increase the availability of iPS cells and services to the HSCI network and the research community at large.

[Read More]

CRISPR/Cas9 U.S. patent board decision appealed

Friday, April 14, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics announced that The Regents of the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively UC), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, have appealed to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) the decision by the Patent Trial and Appeal Board (PTAB) to terminate the interference between certain CRISPR/Cas9 patent claims owned by UC and patents and patent applications owned by the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively Broad).

[Read More]

ReadCoor joins the Wyss Institute’s IARPA MICrONS brain mapping consortium

Tuesday, March 14, 2017

ReadCoor has joined the multi-disciplinary consortium led by the Wyss Institute for Biologically Inspired Engineering at Harvard University to map the brain’s neural circuitry with resolution and precision. The consortium is made possible through a $21 million contract from the Intelligence Advanced Research Projects Activity (IARPA) under the MICrONS program to discover the brain’s learning rules and synaptic ‘circuit design,’ further enhancing neurally-derived machine learning algorithms.

[Read More]